Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSPHENA vs NALBUPHINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective estrogen receptor modulator (SERM) that acts as an estrogen agonist on bone and lipid metabolism, and as an estrogen antagonist on breast and uterine tissue. It mimics estrogen's effects on bone by reducing bone resorption and increasing bone mineral density.
Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.
Treatment of osteoporosis in postmenopausal women at high risk of fracture,Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis,Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
60 mg orally once daily with food.
10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.
The terminal elimination half-life of ospemifene is approximately 26 hours (range 22-39 hours), supporting once-daily dosing.
Terminal elimination half-life is 5 hours; clinically, in hepatic impairment or elderly, half-life may be prolonged up to 8-10 hours.
Extensively metabolized in the liver via glucuronidation (UGT1A8, UGT1A10, UGT2B7) and to a lesser extent by cytochrome P450 (CYP3A4, CYP2C19). Undergoes enterohepatic recycling. Half-life is approximately 5.7 days.
Hepatic metabolism primarily via glucuronidation and oxidative pathways; minor involvement of CYP450 enzymes.
Following oral administration, 50% of a radiolabeled dose is excreted in urine and 35% in feces within 168 hours, primarily as glucuronide conjugates; <1% is excreted unchanged.
Primarily hepatic metabolism; <5% excreted unchanged in urine; about 70% excreted in feces via biliary elimination.
Ospemifene is >99% bound to plasma proteins, primarily albumin.
Approximately 50% bound to plasma proteins, primarily albumin.
The apparent volume of distribution (Vd/F) is approximately 2.4 L/kg, indicating extensive tissue distribution.
2.3 L/kg; indicates extensive tissue distribution, consistent with moderate lipophilicity.
Absolute bioavailability is approximately 30% after oral administration due to first-pass metabolism.
Intravenous: 100%; Intramuscular: approximately 80%; Oral: negligible (<20%) due to extensive first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (Cr Cl <30 m L/min).
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours; Cr Cl <30 m L/min: administer 50% of normal dose every 8 hours.
Child-Pugh A: no adjustment; Child-Pugh B: not recommended; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or use alternative.
Safety and efficacy not established; no specific dosing guidelines.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
No specific dose adjustment; monitor for dysphagia and esophageal adverse effects.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
Increased risk of venous thromboembolic events (including deep vein thrombosis and pulmonary embolism) and death due to stroke. Use is contraindicated in women with active or past history of venous thromboembolism.
Risk of respiratory depression, particularly in opioid-naive patients; risk of dependence and abuse; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Increased risk of venous thromboembolic events and stroke; consider risk-benefit in women at risk for these events. May cause hot flashes and leg cramps. Use with caution in patients with hepatic impairment or history of cholestasis. Not recommended for use in premenopausal women. Discontinue if prolonged immobilization occurs. Monitor lipid profile; may cause small reductions in HDL cholesterol.
Respiratory depression may occur, especially in elderly, cachectic, or debilitated patients,Avoid use in patients with head injury or increased intracranial pressure,May precipitate withdrawal in opioid-dependent patients,Hypotension, biliary tract spasm, and seizure risk
Active or past history of venous thromboembolism (DVT, PE, retinal vein thrombosis), pregnancy (can cause fetal harm), women who are or may become pregnant, nursing mothers, patients with hypersensitivity to raloxifene or any component of the formulation.
Hypersensitivity to nalbuphine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Suspected or known gastrointestinal obstruction
No specific food interactions; take with food to minimize gastrointestinal side effects.
No significant food-drug interactions. Avoid alcohol and grapefruit juice as they may enhance CNS depression.
Ospemifene is contraindicated in pregnancy. Based on its mechanism as a selective estrogen receptor modulator (SERM) and animal studies showing embryotoxicity and teratogenicity, there is potential for fetal harm. First trimester exposure may increase risk of congenital anomalies; second/third trimester exposure may cause urogenital tract abnormalities and endocrine disruption.
FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS) including irritability, hypertonia, tremors, poor feeding. Use only if benefit outweighs risk.
No data on human milk excretion. Ospemifene may suppress lactation due to estrogenic effects. M/P ratio unknown. Avoid breastfeeding during treatment and for at least 2 weeks after last dose.
Excreted in human milk in low concentrations (M/P ratio ~0.6). Relative infant dose estimated 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation and poor feeding. American Academy of Pediatrics considers compatible with breastfeeding with caution.
No dose adjustments studied; contraindicated in pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered clearance) may occur but no data to guide dosing.
No specific dose adjustments recommended for pregnancy. Increased clearance and volume of distribution in third trimester may potentially reduce efficacy; titrate to effect. Avoid in prolonged labor due to risk of fetal bradycardia.
Ospemifene is a selective estrogen receptor modulator (SERM) indicated for moderate to severe dyspareunia due to vulvar and vaginal atrophy in postmenopausal women. Avoid in women with estrogen-dependent neoplasia, unexplained genital bleeding, or prior thromboembolic events. Monitor for endometrial hyperplasia because uterine stimulation can occur. Not for use in premenopausal women.
Nalbuphine is a mixed agonist-antagonist opioid with a ceiling effect for respiratory depression, making it safer than pure agonists. It can precipitate withdrawal in opioid-dependent patients. Monitor for sedation and hypotension. Reversal with naloxone may be less effective. Use with caution in hepatic impairment. Not recommended for chronic pain due to psychotomimetic effects.
Take daily with food to reduce nausea.,Do not take if you have a history of blood clots, breast cancer, or uterine cancer.,Report any unusual vaginal bleeding, breast pain, or leg swelling immediately.,May cause hot flashes, vaginal discharge, or muscle spasms.,Use proper lubricants during intercourse; this medicine does not protect against STIs.,Continue regular pelvic exams and mammograms as recommended.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sleep aids) as they can increase dizziness and drowsiness.,Do not drive or operate heavy machinery until you know how nalbuphine affects you.,Report any signs of withdrawal (e.g., restlessness, tearing, runny nose, yawning, sweating) if you have been taking other opioids.,Seek emergency care if you experience trouble breathing, severe dizziness, or hallucinations.,Do not stop abruptly; tapering may be needed to avoid withdrawal symptoms.
No interactions on record
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSPHENA vs NALBUPHINE, answered by our medical review team.
OSPHENA is a Selective Estrogen Receptor Modulator (SERM) that works by Selective estrogen receptor modulator (SERM) that acts as an estrogen agonist on bone and lipid metabolism, and as an estrogen antagonist on breast and uterine tissue. It mimics estrogen's effects on bone by reducing bone resorption and increasing bone mineral density.. NALBUPHINE is a Opioid Agonist-Antagonist that works by Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSPHENA and NALBUPHINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSPHENA is: 60 mg orally once daily with food.. The standard adult dose of NALBUPHINE is: 10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSPHENA and NALBUPHINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSPHENA is classified as Category C. Ospemifene is contraindicated in pregnancy. Based on its mechanism as a selective estrogen receptor modulator (SERM) and animal studies showing embryotoxicity and teratogenicity, t. NALBUPHINE is classified as Category A/B. FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.